Enhanced stem cell engraftment and modulation of hepatic reactive oxygen species production in diet‐induced obesity
Citations Over TimeTop 25% of 2013 papers
Abstract
Objective The impact of dietary‐induced obesity (DIO) on stem cell engraftment and the respective therapeutic potential of stem cell engraftment in DIO have not been reported. The objectives of this study were to examine the impact of DIO on the survival and efficacy of intravenous bone marrow‐derived mesenchymal stem cell (MSC) administration in the conscious C57BL/6 mouse. Methods Male mice consumed either a chow (CH) or high fat (HF, 60% kcal) diet for 18 weeks and were subsequently treated with MSC over a 6‐day period. Key measurements included tissue‐specific cell engraftment, glucose and insulin sensitivity, inflammation, and oxidative stress. Results MSC administration had no effect on inflammatory markers, glucose, or insulin sensitivity. DIO mice showed increases in MSC engraftment in multiple tissues compared with their CH counterparts. Engraftment was increased in the HF liver where MSC administration attenuated DIO‐induced oxidative stress. These liver‐specific alterations in HF‐MSC were associated with increases in stanniocalcin‐1 (STC1) and uncoupling protein 2 (UCP2), which contribute to cell survival and modulate mitochondrial bioenergetics. Conclusion Results suggest that MSC administration in DIO promotes engraftment and mitigates hepatic oxidative stress. These data invite further exploration into the therapeutic potential of stem cells for the treatment of DIO oxidative stress in the liver.
Related Papers
- → Local Inhibition of Complement Improves Mesenchymal Stem Cell Viability and Function After Administration(2016)62 cited
- → Mesenchymal stem cell therapy in treatment of erectile dysfunction: Autologous or allogeneic cell sources?(2014)32 cited
- → Mesenchymal Stem/Stromal Cells: ASSESSING THE SAFETY AND TOXICITY OF VERY HIGH DOSES OF ALLOGENEIC HUMAN UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS(2023)1 cited
- → Mesenchymal Stem/Stromal Cells: THE EFFECTS OF ADIPOSE TISSUE MESENCHYMAL STEM CELLS (AT-MSCS) ON IMMUNOLOGICAL PATTERNS IN FEMALES WITH MULTIPLE SCLEROSIS(2022)
- → Mesenchymal Stem/Stromal Cells: COMMENCEMENT OF FIRST-IN-HUMAN FOR CLINICAL TRIAL OF ADIPOSE TISSUE DERIVED ALLOGENEIC MESENCHYMAL STEM CELL (ADMSC) SHEETS FOR RETINAL DISEASES(2023)